The presented study demonstrates dose-dependent radiation-responsiveness of a KRAS-driven PDA cell line in conventional radiation biology endpoints such as clonogenicity and in the current concept of irradiation-induced tumour cell immunogenicity. The gene discussed is KRAS; the disease is Patent ductus arteriosus.